BioArctic’s partner Eisai initiates BLA submission of data for lecanemab in China
Stockholm, December 23, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated submission of data for Biologics License Application (BLA) to the National Medical Products Administration (NMPA) of China for lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody.The registration category of lecanemab was designated as a Category 1 drug (innovative biologics not approved in China or any other countries). The data submitted in this package includes data from the Phase IIb clinical trial (Study